This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maschera, B.
Right arrow Articles by Blair, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maschera, B.
Right arrow Articles by Blair, E. D.

 Previous Article  |  Next Article 

J. Virol., 09 1995, 5431-5436, Vol 69, No. 9
Copyright © 1995, American Society for Microbiology

Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors

B Maschera, E Furfine and ED Blair
Gene Targets Group, Wellcome Research Laboratories, Beckenham, United Kingdom.

There are already reports, from clinical trials with human immunodeficiency virus type 1 protease inhibitors, of the emergence of drug-resistant mutants which have one or more point mutations in their protease genes. To examine roles of individual and multiple amino acid substitutions in terms of altered enzyme and virus drug sensitivities, we have produced matched vectors for bacterial expression and virus production. Both vectors accept the same restriction enzyme fragment, produced by PCR or PCR-mutagenesis of the protease gene, allowing parallel expression of mutant enzymes in Escherichia coli and in recombinant viruses. The utility of this vector system was demonstrated by using protease variants glycine to valine at amino acid 48 (G48V) and leucine to methionine at amino acid 90 (L90M) identified after passage of HIV-1 in the Roche phase II clinical trial protease inhibitor Ro 31-8959 (H. Jacobsen, K. Yasargil, D. L. Winslow, J. C. Craig, A. Krohn, I. B. Duncan, and J. Mous, Virology 206:527, 1995). G48V, L90M, and G48V/L90M exhibited successively less processing in vitro than the wild-type enzyme, and the purified enzymes were 220-, 20- , and 720-fold, respectively, less sensitive to Ro 31-8959. The reduced enzyme sensitivity correlated directly with the sensitivities of the matched recombinant viruses, in that individual mutations L90M and G48V conferred 2-fold and 4- to 6-fold increases in 50% inhibitory concentration, respectively, whereas G48V/L90M was 8 to 10 times less sensitive to Ro 31-8959. A proviral vector with the entire protease gene deleted was constructed for use as an in vivo recombination target for an overlapping protease PCR fragment, generating wild-type infectious virus. Finally, direct ligation of restriction fragments, generated from random PCR mutagenesis, into the proviral vector should provide a library of protease mutations that allow extremely rapid selection of highly resistant viral variants.


This article has been cited by other articles:

  • Soares, E. A., Santos, A. F., Gonzalez, L. M., Lalonde, M. S., Tebit, D. M., Tanuri, A., Arts, E. J., Soares, M. A. (2009). Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage. J Antimicrob Chemother 64: 938-944 [Abstract] [Full Text]  
  • Gonzalez, L. M. F., Santos, A. F., Abecasis, A. B., Van Laethem, K., Soares, E. A., Deforche, K., Tanuri, A., Camacho, R., Vandamme, A.-M., Soares, M. A. (2008). Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates. J Antimicrob Chemother 61: 1201-1204 [Abstract] [Full Text]  
  • Gonzalez, L. M. F., Aguiar, R. S., Afonso, A., Brindeiro, P. A., Arruda, M. B., Soares, M. A., Brindeiro, R. M., Tanuri, A. (2006). Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.. J. Gen. Virol. 87: 1303-1309 [Abstract] [Full Text]  
  • Gonzalez, L. M. F., Brindeiro, R. M., Aguiar, R. S., Pereira, H. S., Abreu, C. M., Soares, M. A., Tanuri, A. (2004). Impact of Nelfinavir Resistance Mutations on In Vitro Phenotype, Fitness, and Replication Capacity of Human Immunodeficiency Virus Type 1 with Subtype B and C Proteases. Antimicrob. Agents Chemother. 48: 3552-3555 [Abstract] [Full Text]  
  • Gonzalez, L. M. F., Brindeiro, R. M., Tarin, M., Calazans, A., Soares, M. A., Cassol, S., Tanuri, A. (2003). In Vitro Hypersusceptibility of Human Immunodeficiency Virus Type 1 Subtype C Protease to Lopinavir. Antimicrob. Agents Chemother. 47: 2817-2822 [Abstract] [Full Text]  
  • Weber, J., Rangel, H. R., Chakraborty, B., Tadele, M., Martinez, M. A., Martinez-Picado, J., Marotta, M. L., Mirza, M., Ruiz, L., Clotet, B., Wrin, T., Petropoulos, C. J., Quinones-Mateu, M. E. (2003). A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. J. Gen. Virol. 84: 2217-2228 [Abstract] [Full Text]  
  • Price, D. A., Scullard, G., Oxenius, A., Braganza, R., Beddows, S. A., Kazmi, S., Clarke, J. R., Johnson, G. E., Weber, J. N., Phillips, R. E. (2003). Discordant Outcomes following Failure of Antiretroviral Therapy Are Associated with Substantial Differences in Human Immunodeficiency Virus-Specific Cellular Immunity. J. Virol. 77: 6041-6049 [Abstract] [Full Text]  
  • Parolin, C., Gatto, B., Del Vecchio, C., Pecere, T., Tramontano, E., Cecchetti, V., Fravolini, A., Masiero, S., Palumbo, M., Palu, G. (2003). New Anti-Human Immunodeficiency Virus Type 1 6-Aminoquinolones: Mechanism of Action. Antimicrob. Agents Chemother. 47: 889-896 [Abstract] [Full Text]  
  • Fikkert, V., Cherepanov, P., Van Laethem, K., Hantson, A., Van Remoortel, B., Pannecouque, C., De Clercq, E., Debyser, Z., Vandamme, A.-M., Witvrouw, M. (2002). env Chimeric Virus Technology for Evaluating Human Immunodeficiency Virus Susceptibility to Entry Inhibitors. Antimicrob. Agents Chemother. 46: 3954-3962 [Abstract] [Full Text]  
  • Walter, H., Schmidt, B., Werwein, M., Schwingel, E., Korn, K. (2002). Prediction of Abacavir Resistance from Genotypic Data: Impact of Zidovudine and Lamivudine Resistance In Vitro and In Vivo. Antimicrob. Agents Chemother. 46: 89-94 [Abstract] [Full Text]  
  • Kim, E.-Y., Winters, M. A., Kagan, R. M., Merigan, T. C. (2001). Functional Correlates of Insertion Mutations in the Protease Gene of Human Immunodeficiency Virus Type 1 Isolates from Patients. J. Virol. 75: 11227-11233 [Abstract] [Full Text]  
  • Ikuta, K., Suzuki, S., Horikoshi, H., Mukai, T., Luftig, R. B. (2000). Positive and Negative Aspects of the Human Immunodeficiency Virus Protease: Development of Inhibitors versus Its Role in AIDS Pathogenesis. Microbiol. Mol. Biol. Rev. 64: 725-745 [Abstract] [Full Text]  
  • Schmidt, B., Korn, K., Moschik, B., Paatz, C., Überla, K., Walter, H. (2000). Low Level of Cross-Resistance to Amprenavir (141W94) in Samples from Patients Pretreated with Other Protease Inhibitors. Antimicrob. Agents Chemother. 44: 3213-3216 [Abstract] [Full Text]  
  • Mouroux, M., Yvon-Groussin, A., Peytavin, G., Delaugerre, C., Legrand, M., Bossi, P., Do, B., Trylesinski, A., Diquet, B., Dohin, E., Delfraissy, J. F., Katlama, C., Calvez, V., The MIKADO Study Group, (2000). Early Virological Failure in Naive Human Immunodeficiency Virus Patients Receiving Saquinavir (Soft Gel Capsule)-Stavudine-Zalcitabine (MIKADO Trial) Is Not Associated with Mutations Conferring Viral Resistance. J. Clin. Microbiol. 38: 2726-2730 [Abstract] [Full Text]  
  • Martinez-Picado, J., Sutton, L., De Pasquale, M. P., Savara, A. V., D'Aquila, R. T. (1999). Human Immunodeficiency Virus Type 1 Cloning Vectors for Antiretroviral Resistance Testing. J. Clin. Microbiol. 37: 2943-2951 [Abstract] [Full Text]  
  • Martinez-Picado, J., Savara, A. V., Sutton, L., D'Aquila, R. T. (1999). Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1. J. Virol. 73: 3744-3752 [Abstract] [Full Text]  
  • Rasnick, D., Rasnick, D. (1997). Kinetics Analysis of Consecutive HIV Proteolytic Cleavages of the Gag-Pol Polyprotein. J. Biol. Chem. 272: 6348-6353 [Abstract] [Full Text]  
  • Maschera, B., Darby, G., Palu, G., Wright, L. L., Tisdale, M., Myers, R., Blair, E. D., Furfine, E. S. (1996). Human Immunodeficiency Virus. MUTATIONS IN THE VIRAL PROTEASE THAT CONFER RESISTANCE TO SAQUINAVIR INCREASE THE DISSOCIATION RATE CONSTANT OF THE PROTEASE-SAQUINAVIR COMPLEX. J. Biol. Chem. 271: 33231-33235 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»